BRUKINSA® (zanubrutinib) use across 5 B-cell malignancies, with Dr Tara Graff

Dr Tara Graff, an oncologist from Des Moines, Iowa, discusses the benefits of BRUKINSA across 5 B-cell malignancies.
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:
• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
• Waldenström’s macroglobulinemia (WM)
• Mantle cell lymphoma (MCL) who have received at least one prior therapy
• Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen
• Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy
The MCL, MZL and FL indications are approved under accelerated approval based on overall response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity (including drug-induced liver injury), and embryo-fetal toxicity. In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).
Please see full Prescribing Information: brukinsa.com/prescribing-information.pdf
This content is intended for US Healthcare Professionals only. Learn more at: www.brukinsa.c...